[Study of S-6437 (sustained release cephalexin) in pediatrics (author's transl)].
In order to clinically evaluate S-6437, the following study was carried out in pediatric patients. This clinical study was performed in 30 patients ranging from 2 years and one month to 10 years and one month of age. Seven patients had scarlet fever, 3 acute pharyngitis, 4 acute suppurative tonsillitis, 6 acute bronchitis, 2 acute pneumonia, 3 acute pyelonephritis, 1 chronic pyelonephritis, 2 vaginitis, 1 acute gastro-enteritis, and 1 impetigo. The degree of these diseases were all mild or moderate. These patients were orally administered 35 approximately 50 mg/kg/day in two divided doses for 3 approximately 10 days. As a result, effectiveness of this preparation in these patients was 80% and no side effects were observed.
D000208:Acute Disease; D000367:Age Factors; D001991:Bronchitis / Q000188:drug therapy; D002506:Cephalexin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D005759:Gastroenteritis / Q000188:drug therapy; D006801:Humans; D008297:Male; D010612:Pharyngitis / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy; D011704:Pyelonephritis / Q000188:drug therapy; D012541:Scarlet Fever / Q000188:drug therapy; D013997:Time Factors; D014069:Tonsillitis / Q000188:drug therapy; D014627:Vaginitis / Q000188:drug therapy
D003692:Delayed-Action Preparations; D002506:Cephalexin